Atlas Trials

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Clinical trial NCT05665062 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05665062
Sponsor
Synthekine
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
CLL/SLLNHLMantle Cell LymphomaFollicular LymphomaLarge B-cell LymphomaIndolent B-Cell Non-Hodgkin LymphomaDiffuse Large B Cell Lymphoma
Start date
2023-04-23
Primary completion
2028-06-24
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.